Cytotoxic T lymphocyte activation and expansion

Cytotoxic T lymphocyte activation and expansion encompasses the canonical multi-signal priming of naïve CD8+ T cells by professional antigen-presenting cells, requiring T cell receptor recognition of peptide–MHC class I (signal 1), co-stimulation such as CD28 engagement by B7-1/B7-2 (signal 2), and often inflammatory cytokines such as IL-12 or type I interferons as a “third signal.” Activated CTLs undergo clonal expansion, differentiate into effector cells that kill target cells via perforin/granzyme release at the immune synapse, secrete cytokines such as IFN-γ and TNF-α, and later contract to generate memory subsets. This is a cellular process critical for antiviral and antitumor immunity, not a discrete molecular target or receptor.

Other names

Cytotoxic T cell activationCD8+ T cell activationCTL activationCTL clonal expansionCD8+ T cell clonal expansion

Checkpoint blockade (PD-1/PD-L1, CTLA-4) enhances TCR signaling and co-stimulation during activation/priming to expand functional CTLs—mechanism is release of inhibitory signaling, not binding to a “CTL activation” target. Cytokine agonism (IL-2, IL-12, type I IFNs) provides proliferative/differentiation signals (“third signal”) to drive expansion and cytolytic programming of CTLs via their respective receptors and downstream STAT pathways. Vaccine/adjuvant strategies that increase antigen presentation and co-stimulation by dendritic cells to promote CTL priming (CD28–B7 interactions).